TORONTO, CANADA (January 9, 2019) – PharmaCielo Ltd., the Canadian parent of a Colombian cultivator and producer of medicinal-grade cannabis oil (PharmaCielo Colombia Holdings S.A.S.), today provided a corporate progress update in preparation for its public listing on the TSXV under the ticker PCLO (TSXV:PCLO), on or about January 18, 2019.
In preparation for PharmaCielo’s transition to commercial-scale production and sale of cannabis oil extracts and concentrates in 2019, the Company has made some key appointments to its management team and board of directors:
- With scalable cultivation and processing infrastructure in place and the Company’s public listing achieved, Anthony Wile has stepped down as interim chief executive officer and from the Board as a director, returning to his role as chief executive officer of Grupo Jaque Ltd., a private equity and investment company based in Medellín. Mr. Wile will continue to work with the Company, serving as a special consultant, with efforts focused on actively supporting the long-term global strategy and expanding international opportunities;
- David Attard has been appointed chief executive officer;
- Dr. Delon Human has been appointed global head, health and innovation; and
- Doug Bache has been appointed to the Board, and will serve as chair of the Audit Committee.
“When Federico Cock-Correa and I founded PharmaCielo several years ago, we envisioned an organization that could leverage Colombia’s natural advantages to become a leading global supplier of cannabis products, driving long-term value for shareholders and equally benefitting end users as well as the people of Colombia as a whole,” said Anthony Wile, outgoing CEO. “Earlier this year, I accepted the interim role of CEO to meet the needs of the business during the public listing process as well as to provide leadership in expanding international initiatives as the Company advanced its cultivation and processing capabilities. Over the next several years, PharmaCielo will become a value-added partner and supplier of cannabinoid inputs to global end-product companies. David Attard has a proven track record of scaling profitable operations across multiple markets and distribution channels. I am confident that David and the team are well-positioned to generate profitable growth for shareholders as I return to my role as CEO of Grupo Jaque Ltd. and continue my contribution to the development of PharmaCielo as advisor.”
David Attard, CEO of PharmaCielo, added, “Under Anthony’s leadership, PharmaCielo has constructed a platform with the sophistication and scale to become a value-added cannabinoid provider to some of the world’s largest organizations. Global consumer-facing companies are accustomed to supply chain partners that can provide inputs of a consistently high quality, in large volume. PharmaCielo is positioned to meet this need, as well as to work with these customers to evolve and customize those cannabinoid inputs over time to meet specific product design requirements. We are on strong footing as we launch scale production and sales in 2019. The Company is already producing the highest quality of medicinal-grade cannabis oil, is well capitalized, has near-term revenue opportunities and is engaged in advanced discussions to enter target international jurisdictions.”
One of Mr. Attard’s first initiatives was to appoint Dr. Delon Human as global head of health and innovation. “Delon has been a valuable member of our Board over the past three years, and brings a successful history of driving consumer product development and innovation along with healthcare policy at a global level with large organizations, including those in the pharmaceutical, consumer beverage and tobacco sectors. We expect to complete construction of our large-scale production and innovation facility in Q2-2019 where Delon and his team will expand the development of partnerships with global end-product suppliers, driving innovation and product development to meet the needs of these potential customers.”
Corporate Progress Update
During fiscal 2019, PharmaCielo will focus on:
- scaling the Company’s area under cultivation from 5.3 hectares of open-air greenhouse (~570,487 ft2) currently to approximately 20 hectares (~2.15 million ft2);
- completion of its 2,300 m2 (24,757 ft2) GMP certified Research and Technology Centre oil processing and product innovation facility;
- receipt of registration from the Colombian Ministry of Agriculture for multiple cannabis strains – confirming unrestricted ownership of unique plant genetics for mass cultivation and oil extraction;
- commencement of cannabis oil product sales in key markets for revenue generation;
- confirming agreements with Colombian distributors and end-product manufacturers, to bring consumer products to market;
- finalizing relationships with distributors and end-product manufacturers in select international jurisdictions, to bring products to market;
- receipt of ISO 9001 certification for quality management systems (QMS), confirming operational veracity without review for customers;
- opening of the Company’s first bannered Clínica co-located with Centro Oncológico de Antioquia (COA), part of an oncology practitioner network with complementary objectives focused on treatment of 5 million patients.
PharmaCielo currently has approximately 5.3 hectares of open-air greenhouse (~570,487 feet2) under active cultivation, and plans to steadily increase this area with a goal of cultivating approximately 20 hectares (~2.15 million feet2), by the end of 2019 to meet expected immediate demand. PharmaCielo has approximately 139 hectares (~15 million feet2) of total current cultivation capacity.
Construction of industrial cultivation facilities within or adjacent to indigenous communities will commence in partnership in 2019, as PharmaCielo confirms its leadership in fulfilling licensed producer regulatory obligations to source 10% of production from rural and indigenous communities.
GMP Oil Processing and Product Innovation Facility
PharmaCielo is currently producing both CBD- and THC-dominant cannabis oil extracts in a temporary facility on the site of its nursery and propagation centre for both commercial sale and product research as appropriate. The Company is constructing a 2,300-metre2 oil processing facility (the “Facility”), which provides excess capacity for near-term oil production, with additional space to accommodate modular increases in production capacity as demand for the Company’s products grows. The Facility is expected to be completed during Q2-2019 and to be operational during Q3-2019.
The Facility will also serve as PharmaCielo’s product innovation and development centre under the leadership of Dr. Delon Human. The Company is focused on becoming a value-added partner and supplier of cannabinoid inputs to global end-product companies. The Facility is expected to be a valuable tool as PharmaCielo works to evolve and customize cannabinoid inputs for existing and prospective customers.
The Company entered into a binding letter of intent to acquire UBIQUO, Colombia’s most important medical patient and e-clinic platform (the “Transaction”) in Q2-2018 and expects to close the Transaction in the early weeks of 2019. UBIQUO currently has 85,000 patients on its platform in its home base of Medellín, allowing practitioner and patient access to cannabinoid treatment options. The Company plans to add UBIQUO clinics in seven additional Colombian jurisdictions, which is expected to significantly grow UBIQUO’s patient base and to further extend practitioner access. PharmaCielo expects to have the first of its bannered Clínica open in Q2-2019, as outlined earlier. Each Clínica will maintain a pharmacy presence providing access for medical practitioners and patients to cannabinoid-based treatment options.
Business Development – Colombia
The Company is currently in advanced discussion with targeted product distributors possessing existing relationships with leading Colombian end-product wholesalers and retailers in appropriate health and wellness (and related) verticals. The Company expects to confirm at least one such relationship in 2019 in parallel to certified production facilities coming on-stream, with commencement of product distribution and revenues within 2019.
Business Development – International
The Company is currently finalizing contractual relationships with major partners in key target markets in both Europe and North/Central America, each of whom possesses strong in-market relationships and capacities appropriate to market needs. In these markets, relationship intent is based on effective market strategies of selling medicinal-grade cannabis extracts at scale, through established distributors directly to end-product manufacturers for market distribution. The Company expects to solidify at least two such relationships during 2019 with commencement of product distribution and revenues by Q1-2020.